Our results suggest that the use of a low dose of astemizole with no adverse effects by itself or of an astemizole derivative able to interact with Ptch1 but not with hERG could improve the effectiveness of the standard of care treatment for ACC patients, and could be a promising therapeutic option. The gene discussed is PTCH1; the disease is adrenal cortex carcinoma.